EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial

Xinlei Ma iD, Fan Yang iD, Jinzhi Wu, Bei Xu, Mengdi Jiang, Yiduo Sun iD, Chuanying Sun iD, Ye Yu, Danyi Xu, Lanlan Xiao iD, Chunyun Ren iD, Chunyan Chen und 4 weitere

PLOS Medicine · 29.06.2023 · 20 (6) · e1004249

DOI: 10.1371/journal.pmed.1004249 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 29.06.2023. Verfasst von Xinlei Ma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Polymyalgia rheumatica (PMR) is a common inflammatory disease in elderly persons whose mechanism of pathogenesis has not been elucidated. Glucocorticoids are the main first-line treatments but result in numerous side effects. Therefore, there is a need to explore pathogenetic factors and identify possible glucocorticoid-sparing agents. We aimed to study the pathogenetic features of the disease and assess the efficacy and safety of Janus tyrosine kinase (JAK)-inhibitor tofacitinib in patients with PMR. Methods and findings We recruited treatment-naïve PMR patients from the First Affiliated Hospital, Zhejiang University School of Medicine, between September 2020 and September 2022. In the first cohort, we found that the gene expression patterns of peripheral blood mononuclear cells (PBMCs) in 11 patients (10 female, 1 male, age 68.0 ± 8.3) with newly diagnosed PMR were significantly different from 20 healthy controls (17 female, 3 male, age 63.7 ± 9.8) by RNA sequencing. Inflammatory response and cytokine–cytokine receptor interaction were the most notable pathways affected. We observed marked increases in expression of IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, S100A8, S100A12, and IL17RA, which could trigger JAK signaling. Furthermore, tofacitinib suppressed the IL-6R and JAK2 expression of CD4 + T cells from patients with PMR in vitro . In the second cohort, patients with PMR were randomized and treated with tofacitinib or glucocorticoids (1/1) for 24 weeks. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR activity disease scores (PMR-AS) were calculated. The primary endpoint was the proportion of patients with PMR-AS ≤10 at weeks 12 and 24. Secondary endpoints: PMR-AS score, c-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) at weeks 12 and 24. Thirty-nine patients with newly diagnosed PMR received tofacitinib, and 37 patients received glucocorticoid. Thirty-five patients (29 female, 6 male, age 64.4 ± 8.4) and 32 patients (23 female, 9 male, age 65.3 ± 8.7) patients completed the 24-week intervention, respectively. There were no statistically significant differences in primary or secondary outcomes. At weeks 12 and 24, all patients in both groups had PMR-AS

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyalgia RheumaticaAgedHumansFemaleMaleMiddle AgedGlucocorticoidsLeukocytes, MononuclearPiperidinesC-Reactive ProteinPyrimidines

Substanzen

GlucocorticoidsPiperidinesC-Reactive ProteintofacitinibPyrimidines

Autor:innen und Institutionen

  • Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • AnJi Branch of the First Affiliated Hospital, Zhejiang University School of Medicine, HuZhou, Zhejiang, China.
  • LinHai First People's Hospital, TaiZhou, Zhejiang, China.

ORCID-Profile: Xinlei Ma, Fan Yang, Yiduo Sun, Chuanying Sun, Lanlan Xiao, Chunyun Ren, Weiqian Chen

Förderung

  • Natural Science Foundation of China
  • Key Technologies Research and Development Program

Zitieren

APA

Ma, X., Yang, F., Wu, J., Xu, B., Jiang, M., Sun, Y., Sun, C., Yu, Y., Xu, D., Xiao, L., Ren, C., Chen, C., Ye, Z., Liang, J., Lin, J., & Chen, W. (2023). Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLOS Medicine, 20(6), e1004249. https://doi.org/10.1371/journal.pmed.1004249

Vancouver

Ma X, Yang F, Wu J, Xu B, Jiang M, Sun Y, et al. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLOS Medicine. 2023;20(6):e1004249. doi:10.1371/journal.pmed.1004249

BibTeX
@article{Ma2023,
  author = {Ma, Xinlei and Yang, Fan and Wu, Jinzhi and Xu, Bei and Jiang, Mengdi and Sun, Yiduo and Sun, Chuanying and Yu, Ye and Xu, Danyi and Xiao, Lanlan and Ren, Chunyun and Chen, Chunyan and Ye, Zi and Liang, Junyu and Lin, Jin and Chen, Weiqian},
  title = {Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial},
  journal = {PLOS Medicine},
  year = {2023},
  volume = {20},
  number = {6},
  pages = {e1004249},
  doi = {10.1371/journal.pmed.1004249}
}
Kostenlos starten →